Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Mai 2018 13:34 ET | Quelle: Qu Biologics

Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board

VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
18. April 2018 16:16 ET | Quelle: Qu Biologics

Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease

VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique...
19. Dezember 2017 12:45 ET | Quelle: Qu Biologics

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
28. November 2017 12:43 ET | Quelle: Qu Biologics

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
08. November 2017 16:29 ET | Quelle: Qu Biologics

Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team

VANCOUVER, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
03. Oktober 2017 12:16 ET | Quelle: Qu Biologics

Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers

VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
14. August 2017 13:56 ET | Quelle: Qu Biologics

Positive feedback from FDA reviewers in response to Pre-IND meeting package

VANCOUVER, British Columbia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
02. August 2017 12:29 ET | Quelle: Qu Biologics

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
12. Juli 2017 17:06 ET | Quelle: Qu Biologics

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

VANCOUVER, British Columbia, July 12, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
23. Mai 2017 15:30 ET | Quelle: Qu Biologics

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the...

Vorherige Seite

Nächste Seite